This is a standard annual proxy filing. Traders should note the shareholder vote dates and proposals, but no immediate trading action is required based on this document. Monitor for any unexpected outcomes from the shareholder vote, though the board's unanimous recommendation suggests a low likelihood of surprises.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 27 $79.27entry
- T+1 · 8mo ago +0.23%α +0.58% · $79.45
- T+5 · 8mo ago +2.32%α −1.54% · $81.11
- T+20 · 7mo ago +4.96%α −7.78% · $83.20
- T+60 · 5mo ago +9.69%α −6.00% · $86.95
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Edwards Lifesciences Corp filed a definitive proxy statement (DEFA14A) for its 2026 Annual Meeting of Stockholders, scheduled for May 7, 2026. The filing outlines four proposals for shareholder vote: election of nine directors, an advisory vote on executive compensation, ratification of the independent auditor, and approval of an amended long-term stock incentive program. The board recommends voting in favor of all proposals.
Key Facts
- Filing is a definitive proxy statement (DEFA14A) for the 2026 Annual Meeting of Stockholders.
- Meeting is scheduled for May 7, 2026, and will be held via webcast.
- Proposals include the election of nine directors, an advisory vote on executive compensation, ratification of the independent auditor, and approval of an amended long-term stock incentive program.
- The board of directors recommends a vote in favor of all proposals.
- The filing is routine, administrative, and contains no new financial data or material changes.
Financial Impact
No immediate financial impact. This is a routine governance filing.
Risk Factors
- Low risk of shareholder revolt on any proposal due to the board's strong recommendation.
- Potential for minor governance concerns if any director receives significant withhold votes, though this is not indicated in the filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001099800-26-000016 |
| Document: 0001099800-26-000016-index-headers.html | 0001099800-26-000016 |
| Document: 0001099800-26-000016-index.html | 0001099800-26-000016 |
| Document: 0001099800-26-000016.txt | 0001099800-26-000016 |
Track record
27 reports on EW
1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +4.94% at T+5 after the Nov 4, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 10, 20266d ago Insider Cluster Neutral 3/10 Entry $105.81 Now $107.11 +1.23% settles Nov 18
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $105.81 Now $107.11 +1.23% settles Nov 18
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $105.81 Now $107.11 +1.23% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $104.01 Now $107.11 +2.98% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 3/10 Entry $104.01 Now $107.11 +2.98% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $104.01 Now $107.11 +2.98% settles Nov 17
- Nov 4, 202612d ago 8-K Bullish 6/10 Entry $100.82 to $105.80 Now $107.11 +6.24% ▲ +4.94% +1.65% vs SPY
- Oct 29, 202618d ago Institutional Cluster Neutral 3/10 Entry $94.44 to $100.82 Now $107.11 +13.42% ▲ +6.76% +11.48% vs SPY
- Aug 31, 202611w ago Insider Cluster Neutral 2/10 Entry $90.74 to $86.18 Now $107.11 +18.04% ▼ −5.03% −5.11% vs SPY
- Aug 28, 202611w ago Insider Cluster Neutral 2/10 Entry $90.75 to $86.72 Now $107.11 +18.03% ▼ −4.44% −4.30% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers